BioNTech to buy Biotheus, gaining control of cancer bispecific

BioNTech to buy Biotheus, gaining control of cancer bispecific

Submitted by admin on November 13, 2024 - 11:30am
Source: 
BioPharma Dive
News Tags: 
BioNTech
M&A
Biotheus
Summit Therapeutics
cancer bispecifics
Headline: 
BioNTech to buy Biotheus, gaining control of cancer bispecific
snippet: 

Biotheus’ antibody drug targets PD-L1 and VEGF, a similar design as Summit Therapeutics’ Keytruda-beating ivonescimab.

Do Not Allow Advertisers to Use My Personal information